Search
Menu
Home
HTB
2018
June
HTB
June 2018
Contents
Editorial
29 June 2018: vol 19 no 11: darunavir/cobicistat alert and PK reports
08 June 2018: vol 19 no 10: DTG alert and PK reports
Treatment alerts
New contraindication against using darunavir/cobicistat during pregnancy
Janssen Dear Doctor letter: Prezista (darunavir), Rezolsta ▼(darunavir/cobicistat)and Symtuza ▼(darunavir/cobicistat/emtricitabine/tenofovir alafenamide)
BHIVA statement on potential safety signal in infants born to women conceiving on dolutegravir
ViiV Dear Doctor letter: Neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception
Supplements
Introduction to ART (May 2018)
Conference reports
19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore
Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model
Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole
Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network
Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults
No clinically relevant reduction in oral cabotegravir when co-administered with rifabutin
Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin
Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort
19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore
Dolutegravir 50 mg twice daily sufficient with rifampicin but levels reduced significantly with 100 mg once daily
Vaginal ring reduces efavirenz but not atazanavir exposures
Dispersible paediatric versions of dolutegravir provide higher bioavailability than immediate release formulations
Antiretrovirals
China approves albuvirtide: a once-weekly injectable entry inhibitor
Single dose PRO140 mAb reduces viral load by 0.5 log copies/mL in people with multidrug resistance
EMA approves dolutegravir/rilpivirine (Juluca) in Europe as dual-therapy HIV switch option
Side effects
Boosted darunavir is associated with higher cardiovascular risk in D:A:D study, but not atazanavir
Coinfections and complications
RITA: issue on lung health
HIV prevention and transmission
New FDA guidance for developing PrEP drugs
UK PrEP IMPACT trial announces 3000 new places for gay men but low uptake by women, African and transgender people
Broad PrEP access in Australia reduces HIV infections even with reduced condom use by people not on PrEP
Webcasts on PrEP and women
Cure-related research
Cure research: open access publications
Online database of more than 200 studies on HIV cure research
Community survey on treatment interruptions (ATIs) in cure research
On the web
US community call for coalition for long-term survivors
Sexual identity and HIV
Modern ART in Africa: new resources
PDFs
29 June 2018: vol 19 no 11
08 June 2018: vol 19 no 10
HTB RSS
Current issues
October 2024
September 2024
August 2024
Back issues
Special report
HIV diagnoses in England jump by 51% in 2023: missing targets and highlighting disparities in access to care
6 October 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage